Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma.

Cancer Manag Res · 2010 · PMC3004564 · PMID 21188109

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Patients treated with temsirolimus 175/75 mg had significantly longer progression-free survival than those treated with investigator’s choice therapy; those treated with temsirolimus 175/25 mg showed a trend toward longer progression-free survival.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.